Robert M. Krug

MedicineImmunology and MicrobiologyBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 5 papers. Top paper: “Modeling mitigation of influenza epidemics by baloxavir”.

Modeling mitigation of influenza epidemics by baloxavir

Nature Communications(2020)10.1038/s41467-020-16585-y

N/A

0DataRank · unranked

64 citations

Ciara Nugent, Alison P. Galvani, Robert M. Krug, Lauren Ancel Meyers, Zhanwei Du

Hepatitis C virus drugs that inhibit SARS-CoV-2 papain-like protease synergize with remdesivir to suppress viral replication in cell culture

Cell Reports(2021)10.1016/j.celrep.2021.109133

N/A

0DataRank · unranked

78 citations

Kris M. White, Balasubramanian Harish, Romel Rosales, Theresa A. Ramelot, Thomas Acton +8 more

Structural similarities between SARS-CoV2 3CLpro and other viral proteases suggest potential lead molecules for developing broad spectrum antivirals

Frontiers in Chemistry(2022)10.3389/fchem.2022.948553

N/A

0DataRank · unranked

18 citations

Christopher L. Cioffi, Robert M. Krug, G.T. Montelione, Khushboo Bafna

The public health impact of Paxlovid COVID-19 treatment in the United States

medRxiv(2023)10.1101/2023.06.16.23288870

N/A

0DataRank · unranked

0 citations

Zhanwei Du, Lin Wang, Eric H. Y. Lau, Isaac Chun‐Hai Fung, Petter Holme +5 more

A retrospective cohort study of Paxlovid efficacy depending on treatment time in hospitalized COVID-19 patients

eLife(2024)10.7554/elife.89801

N/A

0DataRank · unranked

11 citations

Lin Wang, Yuan Bai, Yunhu Liu, Eric H. Y. Lau, Alison P. Galvani +4 more